A study investigating the efficacy of anti-CD20 antibody therapy to target CD20+ T-cell lymphoma showed a close relationship between killing efficiency and the surface level of CD20 (11); a challenge also acknowledged in the treatment of CD20+ B-cell lymphomas (27). The gene discussed is MS4A1; the disease is B-cell non-Hodgkin lymphoma.